Stockreport

Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Pat...

Alzamend Neuro, Inc.  (ALZN) 
PDF Safety aspects of AL001 development may qualify for a 505(b)(2) NDA pathway for FDA approval ATLANTA, November 20, 2023 BUSINESS WIRE Alzamend Neuro, Inc. (Nasdaq: AL [Read more]